Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Targeting neuregulin-1 in cartilage homeostasis restoration: Kaempferol-3-o-rutinoside as a novel treatment for osteoarthritis.

Sheng Y., Li S., Wang X., Cui P., Wang Y., Wang Y.

Animal Study on Osteoarthritis, Cartilage Damage, Ligament Injury, Chronic Inflammation, published in Phytomedicine (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Phytomedicine (2025)
Country
Germany
Reported sample size
—
Source database
PubMed
PMID
41308391
DOI
10.1016/j.phymed.2025.157562

Abstract (original English)

Background Osteoarthritis (OA) is a progressive degenerative joint disease with no effective cure. Although Kaempferol-3-O-rutinoside (KR), a naturally occurring flavonoid glycoside, has demonstrated antioxidant and anti-inflammatory effects, however, its therapeutic potential in OA remains unexplored. Purpose This study aimed to investigate the chondroprotective and subchondral bone-preserving effects of KR in OA and to elucidate its underlying molecular mechanisms. Design We assessed the effects of KR on chondrocyte viability, apoptosis, and the expression of inflammatory and catabolic mediators (MMP-13, ADAMTS5), as well as on anabolic markers in vitro. Chondrogenic differentiation was evaluated in adipose-derived mesenchymal stem cells (ADMSCs). We examined the in vivo efficacy of KR using a murine model of OA induced by anterior cruciate ligament transection (ACLT). Treatment outcomes were assessed based on Osteoarthritis Research Society International (OARSI) scoring and subchondral bone microstructural analysis. Finally, we performed mechanistic studies employing RNA sequencing, siRNA-mediated knockdown, and co-immunoprecipitation assays. Results We found that KR enhanced chondrocyte viability, suppressed apoptosis, downregulated inflammatory and catabolic mediators, and upregulated anabolic marker expression in vitro. KR also promoted chondrogenesis in ADMSCs and improv

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsOsteoarthritisChondrocytesMiceKaempferolsMesenchymal Stem CellsNeuregulin-1ApoptosisMice, Inbred C57BLMale

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research